Predictors of attrition in a smoking cessation trial conducted in the lung cancer screening setting

Emily Kim, Randi M Williams, Ellie Eyestone, Marisa Cordon, Laney Smith, Kimberly Davis, George Luta, Eric D Anderson, Brady McKee, Juan Batlle, Michael Ramsaier, Judith Howell, Vicky Parikh, Maria Geronimo, Cassandra Stanton, Raymond Niaura, David Abrams, Kathryn L Taylor, Lung Screening, Tobacco and Health Trial, Emily Kim, Randi M Williams, Ellie Eyestone, Marisa Cordon, Laney Smith, Kimberly Davis, George Luta, Eric D Anderson, Brady McKee, Juan Batlle, Michael Ramsaier, Judith Howell, Vicky Parikh, Maria Geronimo, Cassandra Stanton, Raymond Niaura, David Abrams, Kathryn L Taylor, Lung Screening, Tobacco and Health Trial

Abstract

Significance: Although it is a requirement that tobacco treatment is offered to cigarette smokers undergoing low-dose computed tomographic lung cancer screening (LCS), not all smokers engage in treatment. To understand the barriers to tobacco treatment in this setting, we evaluated predictors of attrition in a smoking cessation trial among individuals undergoing LCS.

Methods: Prior to LCS, 926 participants, 50-80 years old, completed the baseline (T0) phone assessment, including demographic, clinical, tobacco, and psychological characteristics. Following LCS and receipt of the results, participants completed the pre-randomization (T1) assessment.

Results: At the T1 assessment, 735 (79%) participants were retained and 191 (21%) dropped out. In multivariable analyses, attrition was higher among those who: smoked >1 pack per day (OR = 1.44, CI 1.01, 2.06) or had undergone their first (vs. annual) LCS scan (OR = 1.70, CI 1.20, 2.42). Attrition was lower among those with: more education (associates (OR = 0.67, CI = 0.46, 0.98) or bachelor's degree (OR = 0.56, CI 0.35, 0.91) vs. high school/GED), some (vs. none/a little) worry about lung cancer (OR = 0.60, CI 0.39, 0.92), or a screening result that was benign (OR = 0.57, CI 0.39, 0.82) or probably benign (OR = 0.38, CI 0.16, 0.90) vs. negative.

Conclusions: This study illuminated several LCS-related factors that contributed to trial attrition. Increasing tobacco treatment in this setting will require targeted strategies for those who report little lung cancer worry, are undergoing their first LCS exam, and/or who have a negative LCS result. Addressing attrition and reducing barriers to tobacco treatment will increase the likelihood of cessation, thereby reducing the risk of developing lung cancer.

Keywords: Clinical trial; Low-dose computed tomographic lung cancer screening; Smoking cessation; Trial attrition.

Conflict of interest statement

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Copyright © 2021 Elsevier Inc. All rights reserved.

Figures

Figure 1.
Figure 1.
Flow Chart of Study Attrition from Approach to the T1 Assessment

References

    1. Landy R, Young CD, Skarzynski M, et al. Using Prediction-Models to Reduce Persistent Racial/Ethnic Disparities in Draft 2020 USPSTF Lung-Cancer Screening Guidelines. J Natl Cancer Inst. Published online January 5, 2021. doi:10.1093/jnci/djaa211
    1. Ma J, Ward EM, Smith R, Jemal A. Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer. 2013;119(7):1381–1385. doi:10.1002/cncr.27813
    1. Zahnd WE, Eberth JM. Lung Cancer Screening Utilization: A Behavioral Risk Factor Surveillance System Analysis. Am J Prev Med. 2019;57(2):250–255. doi:10.1016/j.amepre.2019.03.015
    1. Recommendation: Lung Cancer: Screening | United States Preventive Services Taskforce. Accessed April 15, 2021.
    1. Aberle DR. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med. 2011;365(5):395–409. doi:10.1056/NEJMoa1102873
    1. Villanti AC, Jiang Y, Abrams DB, Pyenson BS. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PloS One. 2013;8(8):e71379. doi:10.1371/journal.pone.0071379
    1. Centers for Medicare and Medicaid Services, Billioux A, Verlander K, et al. Standardized Screening for Health-Related Social Needs in Clinical Settings: The Accountable Health Communities Screening Tool. NAM Perspect. 2017;7(5). doi:10.31478/201705b
    1. Hahn EJ, Rayens MK, Hopenhayn C, Christian WJ. Perceived risk and interest in screening for lung cancer among current and former smokers. Res Nurs Health. 2006;29(4):359–370. doi:10.1002/nur.20132
    1. Taylor KL, Cox LS, Zincke N, Mehta L, McGuire C, Gelmann E. Lung cancer screening as a teachable moment for smoking cessation. Lung Cancer Amst Neth. 2007;56(1):125–134. doi:10.1016/j.lungcan.2006.11.015
    1. Tammemägi MC, Katki HA, Hocking WG, et al. Selection Criteria for Lung-Cancer Screening. N Engl J Med. 2013;368(8):728–736. doi:10.1056/NEJMoa1211776
    1. Taylor KL, Deros DE, Fallon S, et al. Study protocol for a telephone-based smoking cessation randomized controlled trial in the lung cancer screening setting: the lung screening, tobacco, and health trial. Contemp Clin Trials. 2019;82:25–35. doi:10.1016/j.cct.2019.05.006
    1. Slatore CG, Baumann C, Pappas M, Humphrey LL. Smoking behaviors among patients receiving computed tomography for lung cancer screening. Systematic review in support of the U.S. preventive services task force. Ann Am Thorac Soc. 2014;11(4):619–627. doi:10.1513/AnnalsATS.201312-460OC
    1. Belita E, Sidani S. Attrition in Smoking Cessation Intervention Studies: A Systematic Review. Can J Nurs Res Rev Can Rech En Sci Infirm. 2015;47(4):21–40. doi:10.1177/084456211504700402
    1. Wiseman KP, Coa KI, Prutzman YM. Predictors of Retention in an Adult Text Messaging Smoking Cessation Intervention Program: Cohort Study. JMIR MHealth UHealth. 2019;7(8):e13712. doi:10.2196/13712
    1. Courtney RJ, Clare P, Boland V, et al. Predictors of retention in a randomised trial of smoking cessation in low-socioeconomic status Australian smokers. Addict Behav. 2017;64:13–20. doi:10.1016/j.addbeh.2016.07.019
    1. Bahadir A, Iliaz S, Yurt S, Ortakoylu MG, Bakan ND, Yazar E. Factors affecting dropout in the smoking cessation outpatient clinic. Chron Respir Dis. 2016;13(2):155–161. doi:10.1177/1479972316629953
    1. MacPherson L, Stipelman BA, Duplinsky M, Brown RA, Lejuez CW. Distress tolerance and pre-smoking treatment attrition: examination of moderating relationships. Addict Behav. 2008;33(11):1385–1393. doi:10.1016/j.addbeh.2008.07.001
    1. Metse AP, Hizam NAN, Wiggers J, Wye P, Bowman JA. Factors associated with retention in a smoking cessation trial for persons with a mental illness: a descriptive study. BMC Med Res Methodol. 2018;18(1):177. doi:10.1186/s12874-018-0640-5
    1. Park ER, Gareen IF, Japuntich S, et al. Primary Care Provider-Delivered Smoking Cessation Interventions and Smoking Cessation Among Participants in the National Lung Screening Trial. JAMA Intern Med. 2015;175(9):1509–1516. doi:10.1001/jamainternmed.2015.2391
    1. Steliga MA, Yang P. Integration of smoking cessation and lung cancer screening. Transl Lung Cancer Res. 2019;0(0). Accessed December 8, 2020.
    1. Li J, Chung S, Martinez M, Luft HS. Smoking Cessation Interventions After Lung Cancer Screening Guideline Change. Published online 2020. Accessed December 8, 2020.
    1. Ostroff JS, Copeland A, Borderud SP, Li Y, Shelley DR, Henschke CI. Readiness of Lung Cancer Screening Sites to Deliver Smoking Cessation Treatment: Current Practices, Organizational Priority, and Perceived Barriers. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2016;18(5):1067–1075. doi:10.1093/ntr/ntv177
    1. Wood DE, Kazerooni EA, Baum SL, et al. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN. 2018;16(4):412–441. doi:10.6004/jnccn.2018.0020
    1. American College of Radiology Committee on Lung-RADS®. Lung-RADS Assessment Categories version1.1. Available at . Accessed on April 15, 2021.
    1. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K-O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86(9):1119–1127. doi:10.1111/j.1360-0443.1991.tb01879.x
    1. Apodaca TR, Abrantes AM, Strong DR, Ramsey SE, Brown RA. Readiness to change smoking behavior in adolescents with psychiatric disorders. Addict Behav. 2007;32(6):1119–1130. doi:10.1016/j.addbeh.2006.07.016
    1. Biener L, Abrams DB. The Contemplation Ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol Off J Div Health Psychol Am Psychol Assoc. 1991;10(5):360–365. doi:10.1037//0278-6133.10.5.360
    1. EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy Amst Neth. 1990;16(3):199–208. doi:10.1016/0168-8510(90)90421-9
    1. Kessler RC, Andrews G, Colpe LJ, et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med. 2002;32(6):959–976. doi:10.1017/S0033291702006074
    1. Gul RB, Ali PA. Clinical trials: the challenge of recruitment and retention of participants. J Clin Nurs. 2010;19(1–2):227–233. doi:10.1111/j.1365-2702.2009.03041.x
    1. Pedersen JH, Tønnesen P, Ashraf H. Smoking cessation and lung cancer screening. Ann Transl Med. 2016;4(8). doi:10.21037/atm.2016.03.54
    1. McBride CM, Emmons KM, Lipkus IM. Understanding the potential of teachable moments: the case of smoking cessation. Health Educ Res. 2003;18(2):156–170. doi:10.1093/her/18.2.156
    1. Tammemägi MC, Berg CD, Riley TL, Cunningham CR, Taylor KL. Impact of lung cancer screening results on smoking cessation. J Natl Cancer Inst. 2014;106(6):dju084. doi:10.1093/jnci/dju084
    1. Townsend CO, Clark MM, Jett JR, et al. Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening. Cancer. 2005;103(10):2154–2162. doi:10.1002/cncr.21045

Source: PubMed

3
Iratkozz fel